After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA's Office of Prescription Drug Promotion. The FDA gave Lilly a slap on the wrist ...

The FDA sent a letter to Eli Lilly scolding the drugmaker for Instagram ads it posted for its Type 2 diabetes drug Trulicity. In the letter, dated Jan. 19, the FDA said the ads do not adequately ...

AbbVie’s JAK inhibitor Rinvoq wasn’t even in the top 10 for pharma TV ad spending in February, but it shot up to first place in March as Eli Lilly’s Trulicity dropped down to fifth. Rinvoq is a follow ...

Eli Lilly and Co. has the dubious distinction of receiving the first untitled letter in 2022 from the FDA’s Office of Prescription Drug Promotion. The letter, sent Jan. 19 and posted this week, takes ...

NEW YORK - Many people looking to lose weight are turning to Ozempic and similar drugs. The issue is that those medicines are also used by people with diabetes. One Long Island man who has Type 2 ...